Cargando…
Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity
Increased inflammation caused by SARS-CoV-2 infection can lead to severe coronavirus disease 2019 (COVID-19) and long-term disease manifestations referred to as post-acute sequalae of COVID (PASC). The mechanisms of this variable long-term immune activation are poorly defined. Autoantibodies targeti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571615/ https://www.ncbi.nlm.nih.gov/pubmed/37841848 http://dx.doi.org/10.21203/rs.3.rs-3304083/v1 |
_version_ | 1785120042303619072 |
---|---|
author | Bradley, Todd Geanes, Eric McLennan, Rebecca LeMaster, Cas |
author_facet | Bradley, Todd Geanes, Eric McLennan, Rebecca LeMaster, Cas |
author_sort | Bradley, Todd |
collection | PubMed |
description | Increased inflammation caused by SARS-CoV-2 infection can lead to severe coronavirus disease 2019 (COVID-19) and long-term disease manifestations referred to as post-acute sequalae of COVID (PASC). The mechanisms of this variable long-term immune activation are poorly defined. Autoantibodies targeting immune factors such as cytokines, as well as the viral host cell receptor, angiotensin-converting enzyme 2 (ACE2), have been observed after SARS-CoV-2 infection. Autoantibodies to immune factors and ACE2 could interfere with normal immune regulation and lead to increased inflammation, severe COVID-19, and long-term complications. Here, we deeply pro led the features of ACE2, cytokine, and chemokine autoantibodies in samples from patients recovering from severe COVID-19. We identified epitopes in the catalytic domain of ACE2 targeted by these antibodies, that could inhibit ACE2 function. Levels of autoantibodies targeting ACE2 and other immune factors could serve as determinants of COVID-19 disease severity, and represent a natural immunoregulatory mechanism in response to viral infection. |
format | Online Article Text |
id | pubmed-10571615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Journal Experts |
record_format | MEDLINE/PubMed |
spelling | pubmed-105716152023-10-14 Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity Bradley, Todd Geanes, Eric McLennan, Rebecca LeMaster, Cas Res Sq Article Increased inflammation caused by SARS-CoV-2 infection can lead to severe coronavirus disease 2019 (COVID-19) and long-term disease manifestations referred to as post-acute sequalae of COVID (PASC). The mechanisms of this variable long-term immune activation are poorly defined. Autoantibodies targeting immune factors such as cytokines, as well as the viral host cell receptor, angiotensin-converting enzyme 2 (ACE2), have been observed after SARS-CoV-2 infection. Autoantibodies to immune factors and ACE2 could interfere with normal immune regulation and lead to increased inflammation, severe COVID-19, and long-term complications. Here, we deeply pro led the features of ACE2, cytokine, and chemokine autoantibodies in samples from patients recovering from severe COVID-19. We identified epitopes in the catalytic domain of ACE2 targeted by these antibodies, that could inhibit ACE2 function. Levels of autoantibodies targeting ACE2 and other immune factors could serve as determinants of COVID-19 disease severity, and represent a natural immunoregulatory mechanism in response to viral infection. American Journal Experts 2023-09-29 /pmc/articles/PMC10571615/ /pubmed/37841848 http://dx.doi.org/10.21203/rs.3.rs-3304083/v1 Text en https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Bradley, Todd Geanes, Eric McLennan, Rebecca LeMaster, Cas Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title | Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title_full | Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title_fullStr | Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title_full_unstemmed | Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title_short | Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity |
title_sort | autoantibodies against angiotensin-converting enzyme 2 and immune molecules are associated with covid-19 disease severity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571615/ https://www.ncbi.nlm.nih.gov/pubmed/37841848 http://dx.doi.org/10.21203/rs.3.rs-3304083/v1 |
work_keys_str_mv | AT bradleytodd autoantibodiesagainstangiotensinconvertingenzyme2andimmunemoleculesareassociatedwithcovid19diseaseseverity AT geaneseric autoantibodiesagainstangiotensinconvertingenzyme2andimmunemoleculesareassociatedwithcovid19diseaseseverity AT mclennanrebecca autoantibodiesagainstangiotensinconvertingenzyme2andimmunemoleculesareassociatedwithcovid19diseaseseverity AT lemastercas autoantibodiesagainstangiotensinconvertingenzyme2andimmunemoleculesareassociatedwithcovid19diseaseseverity |